Innohep

Innohep

tinzaparin sodium

Manufacturer:

LEO Pharma

Distributor:

DKSH
Concise Prescribing Info
Contents
Tinzaparin Na
Indications/Uses
DVT & PE. Prevention of post-op DVT in patients undergoing general & orthopaedic surgery. Prevention of clotting in in-dwelling IV lines for extracorporeal circulation & haemodialysis.
Dosage/Direction for Use
Treatment of DVT & PE 175 IU anti-Xa/kg SC once daily. Thromboprophylaxis in patients w/ moderate risk of thrombosis (general surgery) 3,500 IU anti-Xa SC 2 hr before surgery & post-op once daily 3,500 IU anti-Xa for 7-10 days. Thromboprophylaxis in patients w/ high risk of thrombosis (eg, total hip replacement) 4,500 IU anti-Xa SC 12 hr before surgery or 50 IU anti-Xa/kg SC 2 hr before surgery then once daily until the patient has been mobilized. Short-term haemodialysis (<4 hr) Bolus dose of 2,000-2,500 IU anti-Xa into the arterial side of the dialyser (or IV) at the beginning of dialysis. Long-term haemodialysis (>4 hr) A bolus dose of 2,500 IU anti-Xa into the arterial side of the dialyser (or IV) at the beginning of dialysis followed by an infusion of 750 IU anti-Xa/hr. Dose adjustment can be made in steps of 250-500 IU anti-Xa.
Contraindications
Hypersensitivity. Generalized or local haemorrhagic tendency. Uncontrolled severe HTN. Acute cerebral insults. Septic endocarditis. 20,000 anti-Xa IU/mL vial: Contains Na metabisulphite; may cause allergic reactions in predisposed patients. Vial: Contains benzyl alcohol. Do not give to premature babies & neonates due to risk of gasping syndrome.
Special Precautions
Patients w/ hepatic insufficiency. Elderly patients w/ renal impairment. Asses renal function & monitor anti-factor Xa activity in patients w/ severe renal impairment (CrCl <30 mL/min). Do not administer by IM inj due to risk of local haematoma formation. Closely monitor for signs or symptoms of neurological injury in patients receiving medication concurrently w/ spinal or epidural anaesth. Not recommended in pregnant women w/ prosthetic heart valves. Pregnancy.
Adverse Reactions
Priapism & skin necrosis (few cases only).
Drug Interactions
Enhanced anticoagulant effect w/ drugs affecting haemostasis eg, vit K antagonists & dextran.
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AB10 - tinzaparin ; Belongs to the class of heparin group. Used in the treatment of thrombosis.
Presentation/Packing
Form
Innohep inj 10000 AXa iu/mL
Packing/Price
(Vial) 2 mL x 10 × 1's
Form
Innohep inj 20000 AXa iu/mL
Packing/Price
(Vial) 2 mL x 10 × 1's
Form
Innohep pre-filled inj 10000 AXa iu/mL
Packing/Price
(Syringe) 0.35 mL x 10 × 1's; (Syringe) 0.45 mL x 10 × 1's
Form
Innohep pre-filled inj 20000 AXa iu/mL
Packing/Price
(Syringe) 0.5 mL x 2 × 1's; (Syringe) 0.7 mL x 2 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in